Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin)

Transplantation

Volumn 65, Issue 9, 1998, Pages 1272-1274

  Brattström, Christina ^a   Wilczek, Henryk ^a   Tydén, Gunnar ^a   Böttiger, Ylva ^a   Säwe, Juliette ^a   Groth, Carl Gustav ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; PREDNISOLONE; TACROLIMUS;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; PRIORITY JOURNAL;

ADRENAL CORTEX HORMONES; ADULT; CYCLOSPORINE; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PILOT PROJECTS; POLYENES; POSTOPERATIVE COMPLICATIONS; SIROLIMUS;

EID: 0032525253     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199805150-00023     Document Type: Article

References (9)

1. Kahan BD, Pescovitz M, Julian B, Chan G, Vanrenterghem Y and the Sirolimus Multicenter Study Group. Multicenter-phase II trial of sirolimus (SRL) in renal transplantation: six-months results [Abstract 86]. Presented at the XVIth International Congress of the Transplantation Society, Barcelona, Spain, August 25-30, 1996.
2. Murgia MG, Jordan S, Kahan BD. The side-effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996; 49: 209.
3. Lindholm A, Henricsson S. Intra- and interindividual variability in the free fraction of cyclosporine in plasma in recipients of renal transplants. Ther Drug Monit 1989; 11: 623.
4. Editorial. Hyperlipidemia after renal transplantation. Lancet 1988; i: 919.
5. Bittar AE, Ratcliffe PJ, Richardson AJ, et al. The prevalence of hyperlipidemia in renal transplant recipients: association with immunosuppressive and antihypertensive therapy. Transplantation 1990; 50: 987.
6. Emöke D, Wahlberg J, Lithell H, Fellström B. Hyperlipidemia in renal transplantation: risk factor for long-term graft outcome. Eur J Clin Invest 1995; 25: 574.
7. Obispo F, Aswad S, Shidban H, et al. Incidence of new-onset hyperlipidemia in renal transplant patients related with FK506 or cyclosporine based triple therapy [Abstract]. Presented at the 15th Annual Meeting of the American Society of Transplant Physicians, Dallas, TX, May 26-30, 1996.
8. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis 1991; 18: 353.
9. Lindholm A, Welsh M, Alton C, Kahan BD. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: radical differences in bioavailability. Clin Pharmacol Ther 1992; 52(4): 352.